-
公开(公告)号：US20230279012A1
公开(公告)日：2023-09-07
申请号：US18069099
申请日：2022-12-20
申请人： Genentech, Inc.
IPC分类号： C07D487/04 , C07D487/14 , C07D471/04 , C07D471/14 , C07D495/04 , C07D519/00 , A61P37/00 , A61P35/00 , A61K31/496 , A61K31/4985 , A61K31/5025 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D495/14 , C07D498/04 , A61K31/4995 , A61K31/501 , C07D487/08 , C07D513/04 , A61K31/495 , A61K9/20
CPC分类号： C07D487/04 , C07D487/14 , C07D471/04 , C07D471/14 , C07D495/04 , C07D519/00 , A61P37/00 , A61P35/00 , A61K31/496 , A61K31/4985 , A61K31/5025 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D495/14 , C07D498/04 , A61K31/4995 , A61K31/501 , C07D487/08 , C07D513/04 , A61K31/495 , A61K9/20
摘要： Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
-
公开(公告)号：US20240270747A1
公开(公告)日：2024-08-15
申请号：US18523284
申请日：2023-11-29
申请人： Genentech, Inc.
IPC分类号： C07D487/04 , A61K9/20 , A61K31/495 , A61K31/496 , A61K31/4985 , A61K31/4995 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06 , A61P35/00 , A61P37/00 , C07D471/04 , C07D471/14 , C07D487/08 , C07D487/14 , C07D495/04 , C07D495/14 , C07D498/04 , C07D513/04 , C07D519/00
CPC分类号： C07D487/04 , A61K9/20 , A61K31/495 , A61K31/496 , A61K31/4985 , A61K31/4995 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06 , A61P35/00 , A61P37/00 , C07D471/04 , C07D471/14 , C07D487/08 , C07D487/14 , C07D495/04 , C07D495/14 , C07D498/04 , C07D513/04 , C07D519/00
摘要： Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
-
公开(公告)号：US20200024309A1
公开(公告)日：2020-01-23
申请号：US16539947
申请日：2019-08-13
发明人： Peter Andrew SMITH , Tucker Curran ROBERTS , Robert I. HIGUCHI , Prasuna PARASELLI , Michael F. T. KOEHLER , Jacob Bradley SCHWARZ , James John CRAWFORD , Cuong Q. LY , Emily J. HANAN , Huiyong HU , Yongsheng CHEN , Zhiyong YU , Paul Colin Michael WINSHIP , Calum McCleod , Toby Blench
IPC分类号： C07K5/11 , A61P31/04 , A61K9/00 , A61K45/06 , A61K38/07 , C07K5/107 , C07K5/083 , C07K7/06 , A61K38/08 , C07K5/097 , A61K38/06
摘要： Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
-
公开(公告)号：US20210198316A9
公开(公告)日：2021-07-01
申请号：US16539947
申请日：2019-08-13
发明人： Peter Andrew SMITH , Tucker Curran ROBERTS , Robert I. HIGUCHI , Prasuna PARASELLI , Michael F. T. KOEHLER , Jacob Bradley SCHWARZ , James John CRAWFORD , Cuong Q. LY , Emily J. HANAN , Huiyong HU , Yongsheng CHEN , Zhiyong YU , Paul Colin Michael WINSHIP , Calum McCleod , Toby Blench
IPC分类号： C07K5/11 , A61P31/04 , A61K9/00 , A61K45/06 , A61K38/07 , C07K5/107 , C07K5/083 , C07K7/06 , A61K38/08 , C07K5/097 , A61K38/06
摘要： Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
-
公开(公告)号：US20200239519A1
公开(公告)日：2020-07-30
申请号：US15777509
申请日：2016-11-21
发明人： Yongsheng CHEN , Peter Andrew SMITH , Tucker Curran ROBERTS , Robert I. HIGUCHI , Prasuna PARASELLI , Michael F. T. KOEHLER , Jacob Bradley SCHWARZ , James John CRAWFORD , Cuong Q. LY , Huiyong HU , Zhiyong YU
摘要： Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
-
公开(公告)号：US20210188775A1
公开(公告)日：2021-06-24
申请号：US17249457
申请日：2021-03-02
申请人： Genentech, Inc.
发明人： Christian CUNNINGHAM , Paul Powell BEROZA , James John CRAWFORD , Wendy Lee , Olivier RENE , Jason Robert ZBIEG , Jiangpeng LIAO , Tao WANG , Chen YU
IPC分类号： C07D213/76 , C07C311/08 , C07C303/40 , C07C235/46 , C07C231/14 , C07D213/82 , C07D209/08 , C07D237/24
摘要： The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as well as pharmaceutical compositions containing such compounds. The compounds are useful in treating diseases and conditions mediated by TEAD, such as cancer.
-
公开(公告)号：US20180327367A1
公开(公告)日：2018-11-15
申请号：US15777499
申请日：2016-11-21
发明人： Yongsheng CHEN , Peter Andrew SMITH , Tucker Curran ROBERTS , Robert I. HIGUCHI , Prasuna PARASELLI , Michael F. T. KOEHLER , Jacob Bradley SCHWARZ , James John CRAWFORD , Cuong Q. LY , Emily J. HANAN , Huiyong HU , Zhiyong YU
IPC分类号： C07D245/04 , C07K5/02 , A61K38/08 , A61K38/06 , A61K31/496 , A61K31/546 , A61K38/07 , C07K5/087 , C07K5/103 , C07K5/11 , C07K5/113 , C07K5/117 , C07K7/06 , C07K7/08 , C07K9/00 , A61P31/04 , A61K9/00
CPC分类号： C07D245/04 , A61K9/0014 , A61K31/395 , A61K31/407 , A61K31/4196 , A61K31/43 , A61K31/431 , A61K31/496 , A61K31/545 , A61K31/546 , A61K38/06 , A61K38/07 , A61K38/08 , A61K45/06 , A61K2300/00 , A61P31/04 , C07K5/0202 , C07K5/0812 , C07K5/0815 , C07K5/1008 , C07K5/1013 , C07K5/1019 , C07K5/1021 , C07K5/1024 , C07K7/06 , C07K7/08 , C07K9/008 , Y02A50/404 , Y02A50/406
摘要： Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
-
![2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS](/abs-image/US/2024/05/30/US20240174696A1/abs.jpg.150x150.jpg)
公开(公告)号：US20240174696A1
公开(公告)日：2024-05-30
申请号：US18526572
申请日：2023-12-01
申请人： Genentech, Inc.
发明人： Steven John MCKERRALL , Alice Rose WONG , James John CRAWFORD , Wendy LEE , Kwong Wah LAI , Guillaume PELLETIER , Stéphanie ROY , Dana Krystin WINTER , Mikiko OKUMURA , Ruth Dorel
IPC分类号： C07D519/00 , A61P11/00
CPC分类号： C07D519/00 , A61P11/00
摘要： Disclosed are 2,8-diazaspiro[4.5]decane compounds, including (pyrido[3,4-d]pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane compounds, (2,6-naphthyridin-1-yl)-2,8-diazaspiro[4.5]decane compounds, and (1,7-naphthyridin-4-yl)-2,8-diazaspiro[4.5]decane compounds, that are inhibitors of LATS1/2, compositions containing these compounds, and methods for inhibiting LATS1/2 activity.
-
公开(公告)号：US20210079002A1
公开(公告)日：2021-03-18
申请号：US17001205
申请日：2020-08-24
申请人： Genentech, Inc.
IPC分类号： C07D487/04 , C07D487/14 , C07D471/04 , C07D471/14 , C07D495/04 , C07D519/00 , A61P37/00 , A61P35/00 , A61K31/496 , A61K31/4985 , A61K31/5025 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D495/14 , C07D498/04 , A61K31/4995 , A61K31/501 , C07D487/08 , C07D513/04 , A61K31/495 , A61K9/20
摘要： Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
-
公开(公告)号：US20200062769A1
公开(公告)日：2020-02-27
申请号：US16670898
申请日：2019-10-31
申请人： Genentech, Inc.
IPC分类号： C07D487/04 , A61K9/20 , A61K31/495 , C07D513/04 , C07D487/08 , A61K31/501 , A61K31/4995 , C07D498/04 , C07D495/14 , A61K45/06 , A61K31/5383 , A61K31/5377 , A61K31/53 , A61K31/506 , A61K31/5025 , A61K31/4985 , A61K31/496 , C07D519/00 , C07D495/04 , C07D471/14 , C07D471/04 , C07D487/14 , A61P35/00 , A61P37/00
摘要： Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.037 秒)
